$121,795,918

FDA-led public-private partnerships to accelerate drug development and regulatory science innovation through the Critical Path Initiative.

Streamlines FDA approval pathways and reduces time-to-market for therapeutics, directly impacting U.S. pharmaceutical competitiveness and patient access to new medicines.

Strengthens collaboration between FDA, pharma companies, and research institutions, potentially accelerating adoption of new manufacturing and analytical standards across the biotech supply chain.

Enhances U.S. regulatory efficiency and innovation speed in drug development, countering China's growing biotech R&D investments and faster approval timelines in some therapeutic areas.